{"id":775435,"date":"2023-08-04T05:03:42","date_gmt":"2023-08-04T09:03:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/"},"modified":"2023-08-04T05:03:42","modified_gmt":"2023-08-04T09:03:42","slug":"cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/","title":{"rendered":"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEWARK, Calif., Aug.  03, 2023  (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2023 and to provide a business update.<\/p>\n<p align=\"justify\">\n        <strong>Conference Call Details<\/strong><br \/>\n        <br \/>To access the live conference call, please dial 877-308-2053 from the U.S. and Canada, or 212-231-2921 internationally, Conference ID # 22027740. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L1ZHzHqCgme1VSWJG1x4oUS2BY-6NVjNlXx1YYs6vy-VAhy7P39jPIGNtqi5WkOAi7Lur3A7q7ULbQgVTjsKTh4aTFZUi7mg3VpBHip5qR4=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/ir.cymabay.com\/events<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About CymaBay <\/strong>\n      <\/p>\n<p align=\"justify\">CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), Priority Medicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class investigational treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LZgmrwsP2r8UReQxUmjeN4qT7CMWn_duvvLoEtAcmiSeIr1Jrdq-wgo5IJWEguhjP_bclACBD3eQYgY-Zisa1g==\" rel=\"nofollow noopener\" target=\"_blank\">www.cymabay.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ln4OfJBFiW8idZsBOETT-8dkv0EZYuMPupfHUKbURy50Yvcf6adYU4RjmbOSk3apxUvfky7OFcPF40fGacL6c7XIK6C-0yYqljSjDK78x9c=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bzgil0wYapSREDNeiERz46OLGybC4QJ2XcmqZOlOWqN6jYL8SMLwVnxsP-NCbR4p3Lptz1GR0ZDMXbTfxoIogDIMXs_MhDnsCywm27VNHZI6TtFI3BkNlPB4nTmUjxcL\" rel=\"nofollow noopener\" target=\"_blank\">Linkedin<\/a>.<\/p>\n<p>\n        <strong>Public Relations Contact<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>Theresa\u00a0Dolge<br \/>Evoke Kyne<br \/>(609) 915-2156<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gnPlg-pJrBIthgs7cqebE1Mjbii6OBfa0LAvB1hYqmdK_KSVFT9duMBxDbhJBI1rN80mV7vqa_8wlkKrrFI6FVL87_f4PAD3ia0pzlqJ0aVNrfbPmCQN1qCIjtfhYscU\" rel=\"nofollow noopener\" target=\"_blank\">Theresa.Dolge@evokegroup.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong>\n      <\/p>\n<p>Hans Vitzthum<br \/>LifeSci Advisors, LLC<br \/>(617) 430-7578<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dCrFfkoNruhcmjohPDpsEubrEzmlx3ckcmX2j1ZXmfXQILKZun4BoqrWU3OJFk534VSkNykxnuLDWAhidNSOZoFkBKJSitlGeloaUD9OHHAJi-u7G_c4DVBxHGt275jsZbO3OIaVDzIRKJjr5WthrN-VEXlhwn8J511XrlSxRQVo3NLa97FVXSstPRfnN4R-yCJUpZmN3ypSv_Dt0xZp88-OhEm83Ir_mOxwa17ojSujgDwoQ6TEsBhduIXYvouTUj-DEfFx1CUR6777tLgUXA==\" rel=\"nofollow noopener\" target=\"_blank\">Hans@LifeSciAdvisors.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjBlNGU0YWUtNGI5Yy00OTk4LWI4ZDktYTU3Zjg0ZmYwYzVkLTEwMzkzODk=\/tiny\/CymaBay-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2023 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-308-2053 from the U.S. and Canada, or 212-231-2921 internationally, Conference ID # 22027740. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at http:\/\/ir.cymabay.com\/events. About &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-775435","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2023 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-308-2053 from the U.S. and Canada, or 212-231-2921 internationally, Conference ID # 22027740. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at http:\/\/ir.cymabay.com\/events. About &hellip; Continue reading &quot;CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-04T09:03:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023\",\"datePublished\":\"2023-08-04T09:03:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/\"},\"wordCount\":286,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/\",\"name\":\"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=\",\"datePublished\":\"2023-08-04T09:03:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/","og_locale":"en_US","og_type":"article","og_title":"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 - Market Newsdesk","og_description":"NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) &#8212; CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2023 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-308-2053 from the U.S. and Canada, or 212-231-2921 internationally, Conference ID # 22027740. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company&#8217;s website at http:\/\/ir.cymabay.com\/events. About &hellip; Continue reading \"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-04T09:03:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023","datePublished":"2023-08-04T09:03:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/"},"wordCount":286,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/","name":"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=","datePublished":"2023-08-04T09:03:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4NjQ4MSM1NzM0NjM1IzIwMjgzMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cymabay-therapeutics-to-report-second-quarter-of-2023-financial-results-on-thursday-august-10-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=775435"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775435\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=775435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=775435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=775435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}